Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 vaccine (Vero cell), inactivated (Beijing Institute of Biological Products)
- Development stage
- Unknown
- Lead developer
- Sinovac Life Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
COVID‑19 vaccine (Vero cell), inactivated, refers to a class of vaccines developed using whole SARS-CoV‑2 virus that has been grown in Vero cells and then chemically inactivated so it cannot cause disease. The main mechanism is to induce an immune response by presenting the body with the entire killed virus, prompting production of neutralizing antibodies against SARS-CoV‑2. These vaccines are adjuvanted with aluminum hydroxide to enhance immunogenicity. They are indicated for active immunization to prevent COVID‑19 caused by SARS-CoV‑2, and have been shown in clinical trials to reduce symptomatic infection and severe outcomes[1][4][7]. Multiple products exist under this name, most notably those developed by Sinopharm’s Beijing Institute of Biological Products (“COVILO”, also known as BBIBP-CorV) and Sinovac (“CoronaVac”). Both have received emergency or conditional approval globally.
- Brand names
- COVILOCoronaVacHayat-VaxZhong'aikewei
- Other names
- Sinopharm BIBP COVID-19 vaccineSinovac COVID‑19 Vaccine (for CoronaVac)
Beyond the preview
Go deeper on COVID-19 vaccine (Vero cell), inactivated (Beijing Institute of Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 vaccine (Vero cell), inactivated (Beijing Institute of Biological Products).